Pacira BioSciences (NASDAQ:PCRX – Get Free Report) was upgraded by stock analysts at Truist Financial from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday,Finviz reports. The firm presently has a $25.00 price objective on the stock, up from their prior price objective of $8.00. Truist Financial’s price objective points to a potential downside of 3.96% from the company’s previous close.
A number of other brokerages have also recently commented on PCRX. Barclays dropped their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and issued a $39.00 target price on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Needham & Company LLC upped their price target on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences has an average rating of “Hold” and a consensus price target of $26.20.
View Our Latest Stock Analysis on Pacira BioSciences
Pacira BioSciences Trading Up 1.1 %
Hedge Funds Weigh In On Pacira BioSciences
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Caitlin John LLC raised its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after buying an additional 2,749 shares during the period. CWM LLC increased its holdings in shares of Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after buying an additional 5,716 shares during the period. Virtus Investment Advisers Inc. bought a new stake in shares of Pacira BioSciences in the 3rd quarter valued at about $98,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after acquiring an additional 3,404 shares during the period. 99.73% of the stock is currently owned by hedge funds and other institutional investors.
About Pacira BioSciences
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Read More
- Five stocks we like better than Pacira BioSciences
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- Earnings Per Share Calculator: How to Calculate EPS
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- Investing in the High PE Growth Stocks
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.